Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs M Versteegh

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 25, 2011
Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5DMatthijs M Versteegh, Annemieke Leunis, Jolanda J Luime, et al.
Clinical and Translational Radiation Oncology|August 22, 2025
Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal studyYi Hsuan Chen, Michiel Kroesen, Mischa S Hoogeman, et al.
Pharmacoeconomics|May 29, 2019
Severity-Adjusted Probability of Being Cost EffectiveMatthijs M Versteegh, Isaac Corro Ramos, Nasuh C Buyukkaramikli, et al.
Pharmacoeconomics|August 23, 2025
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's DiseaseMatthijs M Versteegh, Simone A Huygens, Inigo Bermejo, et al.
BMJ Open|July 30, 2015
Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makersSaskia de Groot, Adriana J Rijnsburger, Matthijs M Versteegh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Dutch Tariff for the Five-Level Version of EQ-5DMatthijs M Versteegh, Karin M Vermeulen, Silvia M A A Evers, et al.
Health and Quality of Life Outcomes|July 22, 2020
Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness modelMira D Franken, Anne de Hond, Koen Degeling, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic GuidelinesIsaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 18, 2020
Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment OptionsMarcel F Jonker, Bas Donkers, Lucas M A Goossens, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 25, 2011
Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5DMatthijs M Versteegh, Annemieke Leunis, Jolanda J Luime, et al.
Clinical and Translational Radiation Oncology|August 22, 2025
Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal studyYi Hsuan Chen, Michiel Kroesen, Mischa S Hoogeman, et al.
Pharmacoeconomics|May 29, 2019
Severity-Adjusted Probability of Being Cost EffectiveMatthijs M Versteegh, Isaac Corro Ramos, Nasuh C Buyukkaramikli, et al.
Pharmacoeconomics|August 23, 2025
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's DiseaseMatthijs M Versteegh, Simone A Huygens, Inigo Bermejo, et al.
BMJ Open|July 30, 2015
Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makersSaskia de Groot, Adriana J Rijnsburger, Matthijs M Versteegh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Dutch Tariff for the Five-Level Version of EQ-5DMatthijs M Versteegh, Karin M Vermeulen, Silvia M A A Evers, et al.
Health and Quality of Life Outcomes|July 22, 2020
Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness modelMira D Franken, Anne de Hond, Koen Degeling, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic GuidelinesIsaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 18, 2020
Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment OptionsMarcel F Jonker, Bas Donkers, Lucas M A Goossens, et al.
Pageof 3